Surveillance and outbreak report Open Access
Like 0


Extended-spectrum beta-lactamase-producing (ESBL-E) are a major focus of multidrug-resistant organisms (MRO) surveillance programmes in France. To describe the temporal and geographical trends of these pathogens, we conducted an epidemiological study based on data extracted from the nationwide MRO surveillance network from 2009 to 2013. During this time, the incidence of ESBL-E infections in French hospitals increased by 73%, from 0.35 to 0.60 per 1,000 patient days (PD) (p < 0.001) and ESBL-E bacteraemia by 77%, from 0.03 to 0.05 per 1,000 PD (p < 0.001). The incidence of ESBL-E infections was higher in intensive-care units (1.62 to 2.44 per 1,000 PD (p < 0.001)) than in recovery and long-term care facilities (0.20 to 0.31 per 1,000 PD (p < 0.001)). was the most frequent extended-spectrum beta-lactamase-producing (ESBL) pathogen, representing 59% (26,238/44,425) of all ESBL isolates, followed by (20%; 8,856/44,425) in 2013. The most frequent infection was urinary tract infection, for all species. The incidence of ESBL-E varied by region but showed an upward trend overall. Reinforcement of control measures for halting the spread of such MRO is crucial.


Article metrics loading...

Loading full text...

Full text loading...



  1. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23(3):163-7.  https://doi.org/10.1007/s10096-003-1084-2  PMID: 14986159 
  2. Stewardson A, Fankhauser C, De Angelis G, Rohner P, Safran E, Schrenzel J, et al. Burden of bloodstream infection caused by extended-spectrum β-lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infect Control Hosp Epidemiol. 2013;34(2):133-43.  https://doi.org/10.1086/669086  PMID: 23295559 
  3. Wegner C, Hübner NO, Gleich S, Thalmaier U, Krüger CM, Kramer A. One-day point prevalence of emerging bacterial pathogens in a nationwide sample of 62 German hospitals in 2012 and comparison with the results of the one-day point prevalence of 2010. GMS Hyg Infect Control. 2013;8(1):Doc12. PMID: 23967398 
  4. Zarb P, Coignard B, Griskeviciene J, Muller A, Vankerckhoven V, Weist K, et al. National Contact Points for the ECDC pilot point prevalence surveyHospital Contact Points for the ECDC pilot point prevalence survey. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill. 2012;17(46):20316. PMID: 23171822 
  5. Réseau d’alerte, d’investigation et de surveillance des infections nosocomiales (RAISIN). Enquête nationale de prévalence des infections nosocomiales et des traitements anti-infectieux en établissements de santé, France, mai-juin 2012. Résultats. [2012 national prevalence survey of nosocomial infections and anti-infection treatments in healthcare facilities. May-June 2012. Results]. Saint-Maurice: Institut de veille sanitaire; 2013. [Accessed 2 Sep 2015]. French. Available from: http://www.invs.sante.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-infectieuses/2013/Enquete-nationale-de-prevalence-des-infections-nosocomiales-et-des-traitements-anti-infectieux-en-etablissements-de-sante-France-mai-juin-2012
  6. Goulenok T, Ferroni A, Bille E, Lécuyer H, Join-Lambert O, Descamps P, et al. Risk factors for developing ESBL E. coli: can clinicians predict infection in patients with prior colonization? J Hosp Infect. 2013;84(4):294-9.  https://doi.org/10.1016/j.jhin.2013.04.018  PMID: 23846237 
  7. Birgand G, Armand-Lefevre L, Lolom I, Ruppe E, Andremont A, Lucet JC. Duration of colonization by extended-spectrum β-lactamase-producing Enterobacteriaceae after hospital discharge. Am J Infect Control. 2013;41(5):443-7.  https://doi.org/10.1016/j.ajic.2012.05.015  PMID: 22998785 
  8. Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F, Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol. 2004;42(10):4769-75.  https://doi.org/10.1128/JCM.42.10.4769-4775.2004  PMID: 15472339 
  9. Carbonne A, Arnaud I, Maugat S, Marty N, Dumartin C, Bertrand X, et al. MDRB Surveillance National Steering Group (BMR-Raisin). National multidrug-resistant bacteria (MDRB) surveillance in France through the RAISIN network: a 9 year experience. J Antimicrob Chemother. 2013;68(4):954-9.  https://doi.org/10.1093/jac/dks464  PMID: 23194721 
  10. Jarlier V, Trystram D, Brun-Buisson C, Fournier S, Carbonne A, Marty L, et al. Collégiale de Bactériologie-Virologie-Hygiène des Hôpitaux Universitaires de l’Ile de France. Curbing methicillin-resistant Staphylococcus aureus in 38 French hospitals through a 15-year institutional control program. Arch Intern Med. 2010;170(6):552-9.  https://doi.org/10.1001/archinternmed.2010.32  PMID: 20308642 
  11. Lowe CF, Katz K, McGeer AJ, Muller MPToronto ESBL Working Group. Efficacy of admission screening for extended-spectrum beta-lactamase producing Enterobacteriaceae. PLoS ONE. 2013;8(4):e62678.  https://doi.org/10.1371/journal.pone.0062678  PMID: 23638132 
  12. Gibold L, Robin F, Tan RN, Delmas J, Bonnet R. Four-year epidemiological study of extended-spectrum β-lactamase-producing Enterobacteriaceae in a French teaching hospital. Clin Microbiol Infect. 2014;20(1):O20-6.  https://doi.org/10.1111/1469-0691.12321  PMID: 23927626 
  13. Kassakian SZ, Mermel LA. Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteria. Antimicrob Resist Infect Control. 2014;3(1):9.  https://doi.org/10.1186/2047-2994-3-9  PMID: 24666610 
  14. Soussy CJ, Carret G, Cavallo JD, Chardon H, Chidiac C, Choutet P, et al. [Antibiogram Committee of the French Microbiology Society. Report 2000-2001]. Pathol Biol (Paris). 2000;48(9):832-71. PMID: 11141919 
  15. French Society of Microbiology (SFM). Comité de l’antibiogramme de la Société Française de Microbiologie. Recommandation 2015. [Committee for Antimicrobial Testing of the French Society of Microbiology. 2015 recommendations]. Paris: SFM. [Accessed 2 Sep 2015]. French. Available from: http://www.sfm-microbiologie.org/UserFiles/files/casfm/CASFMV2_220715.pdf
  16. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1988;10(4):867-78.  https://doi.org/10.1093/clinids/10.4.867  PMID: 3263690 
  17. Lin M, Weinstein RA, Hayden MK. Multiply drug-resistant pathogens: epidemiology and control. In: Jarvis WR, editor. Bennett & Brachman’s hospital infections. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 193-222.
  18. Reich F, Atanassova V, Klein G. Extended-spectrum β-lactamase- and AmpC-producing enterobacteria in healthy broiler chickens, Germany. Emerg Infect Dis. 2013;19(8):1253-9.  https://doi.org/10.3201/eid1908.120879  PMID: 23876576 
  19. Geser N, Stephan R, Hächler H. Occurrence and characteristics of extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae in food producing animals, minced meat and raw milk. BMC Vet Res. 2012;8(1):21.  https://doi.org/10.1186/1746-6148-8-21  PMID: 22397509 
  20. van Hoek AH, Schouls L, van Santen MG, Florijn A, de Greeff SC, van Duijkeren E. Molecular characteristics of extended-spectrum cephalosporin-resistant Enterobacteriaceae from humans in the community. PLoS ONE. 2015;10(6):e0129085.  https://doi.org/10.1371/journal.pone.0129085  PMID: 26029910 
  21. Vaux S, Carbonne A, Thiolet JM, Jarlier V, Coignard BRAISIN and Expert Laboratories Groups. Emergence of carbapenemase-producing Enterobacteriaceae in France, 2004 to 2011. Euro Surveill. 2011;16(22):19880. PMID: 21663708 
  22. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance interactive database (EARS-Net). Stockholm: ECDC. [Accessed 2 Sep 2015]. Available from: http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx#sthash.goMy0HLp.dpuf
  23. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2013. Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012.pdf
  24. Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE, Castanheira M. Resistance surveillance program report for selected European nations (2011). Diagn Microbiol Infect Dis. 2014;78(4):429-36.  https://doi.org/10.1016/j.diagmicrobio.2013.10.008  PMID: 24440509 
  25. Institut de Veille Sanitaire (InVS). Signalement externe des infections nosocomiales. E-SIN. [External reporting of nosocomial infections. E-SIN]. Saint Maurice: InVS. [Accessed 2 Sep 2015]. Available from: http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Infections-associees-aux-soins/Signalement-et-alertes/Signalement-externe-des-infections-nosocomiales
  26. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011;66(2):398-407.  https://doi.org/10.1093/jac/dkq412  PMID: 21106563 
  27. Institut de Veille Sanitaire (InVS). Surveillance des bactéries multiresistantes dans les établissements de santé français. Réseau BMR-Raisin – Données 2012, France 01-01-2014. [Surveillance of multidrug-resistant bacteria in Ffrench health care facilities. MRO RAISIN network. 2012 results. France, 01-01-2014]. Saint Maurice: InVS. [Accessed 3 Sep 2015]. French. Available from: http://www.invs.sante.fr/pmb/invs/%28id%29/PMB_12101
  28. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother. 2014;58(2):833-8.  https://doi.org/10.1128/AAC.01896-13  PMID: 24247134 
  29. Fernandes R, Amador P, Oliveira C, Prudêncio C. Molecular Characterization of ESBL-Producing Enterobacteriaceae in Northern Portugal. ScientificWorldJournal. 2014;2014:782897. doi: 10.1155/2014/782897
  30. Institut de Veille Sanitaire (InVS). Episodes impliquant des entérobactéries productrices de carbapénèmases en France. Situation épidémiologique du 4 mars 2015. [Episodes involving carbapenemases producing enterobacteria in France. Epidemiological situation of March 4, 2015]. Saint Maurice: InVS. [Accessed 2 Sep 2015]. Available from: http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Infections-associees-aux-soins/Surveillance-des-infections-associees-aux-soins-IAS/Enterobacteries-productrices-de-carbapenemases-EPC/Episodes-impliquant-des-enterobacteries-productrices-de-carbapenemases-en-France.-Situation-epidemiologique-du-4-mars-2015
  31. Djahmi N, Dunyach-Remy C, Pantel A, Dekhil M, Sotto A, Lavigne JP. Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries. Biomed Res Int. 2014;2014:305784.

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error